Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Slomovitz

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|December 17, 2003
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesBrian M Slomovitz, Thomas W Burke, Patricia J Eifel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancerLarissa A Meyer, Brian M Slomovitz, Bojana Djordjevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinomaBrian M Slomovitz, Yunyun Jiang, Melinda S Yates, et al.
Gynecologic Oncology|March 16, 2021
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundationBradley J Monk, Robert L Coleman, Thomas J Herzog, et al.
Gynecologic Oncology|January 22, 2022
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, et al.
Cancer Research Communications|August 5, 2022
The vaginal microbiome is associated with endometrial cancer grade and histologyHesamedin Hakimjavadi, Sophia H George, Michael Taub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO TrialJung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Gynecologic Oncology|August 26, 2020
State of the science: Uterine sarcomas: From pathology to practiceAlexander Shushkevich, Premal H Thaker, Ramey D Littell, et al.
Obstetrics and Gynecology|September 2, 2006
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutationsKathleen M Schmeler, Charlotte C Sun, Diane C Bodurka, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|December 17, 2003
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesBrian M Slomovitz, Thomas W Burke, Patricia J Eifel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancerLarissa A Meyer, Brian M Slomovitz, Bojana Djordjevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinomaBrian M Slomovitz, Yunyun Jiang, Melinda S Yates, et al.
Gynecologic Oncology|March 16, 2021
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundationBradley J Monk, Robert L Coleman, Thomas J Herzog, et al.
Gynecologic Oncology|January 22, 2022
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation studyBrian M Slomovitz, Virginia L Filiaci, Joan L Walker, et al.
Cancer Research Communications|August 5, 2022
The vaginal microbiome is associated with endometrial cancer grade and histologyHesamedin Hakimjavadi, Sophia H George, Michael Taub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO TrialJung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Gynecologic Oncology|August 26, 2020
State of the science: Uterine sarcomas: From pathology to practiceAlexander Shushkevich, Premal H Thaker, Ramey D Littell, et al.
Obstetrics and Gynecology|September 2, 2006
Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutationsKathleen M Schmeler, Charlotte C Sun, Diane C Bodurka, et al.
Pageof 11